Sean Hashmi, MD
A trial of 3,533 people with type 2 diabetes and chronic kidney disease was stopped early in late 2023. Not because something went wrong. Because the drug worked so well that leaving anyone on placebo was no longer ethical. That drug was Ozempic. Eight months later, the FDA approved semaglutide for a reason that has nothing to do with weight loss. In this episode, Dr. Sean Hashmi breaks down the FLOW trial, the diabetic kidney disease study that changed the standard of care. Patients on semaglutide saw a 24 percent reduction in the composite kidney outcome, a 38 percent drop in albuminuria, an 18 percent reduction in major adverse cardiovascular events, and a 20 percent reduction in all-cause mortality across three and a half years of follow-up. The patients in the trial were already on standard care: ACE inhibitors or ARBs, often metformin, sometimes SGLT2 inhibitors. The semaglutide benefit was stacked on top, and the effects were additive. Dr. Sean Hashmi covers the four mechanisms behind the kidney benefit. Glucose control reduces glycation and oxidative stress in the small vessels feeding the kidney. Weight loss of 10 to 15 percent at higher doses reduces the inflammatory load on every organ. Modest blood pressure reduction and natriuresis lower the force pushing on the inside of the kidney filter. And the mechanism that makes this drug a true kidney-saving therapy: GLP-1 receptors sit on immune cells, on the cells lining blood vessels, and inside the kidney itself, and activating them appears to dampen the chronic low-grade inflammation that drives diabetic kidney scarring. The episode walks through the four actionable steps every patient with type 2 diabetes and CKD should take before their next appointment. Pull the last lab panel and find the eGFR and the urine albumin-to-creatinine ratio. Bring the FLOW trial up at the visit with the exact words Dr. Sean recommends. Build a sick day plan at the prescribing visit because dehydration on a GLP-1 can spiral into acute kidney injury fast. Defend muscle mass with resistance training two or three sessions a week and adequate protein for your kidney stage. The one absolute contraindication: personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia. JOIN THE NEWSLETTER for weekly evidence-based kidney, metabolic, and longevity research: https://selfprinciple.org/newsletter Learn more about Dr. Sean Hashmi and SELFPrinciple.org, a 501(c)(3) nonprofit: https://selfprinciple.org CONNECT YouTube: https://youtube.com/@SeanHashmiMD Instagram: https://instagram.com/seanhashmimd DISCLAIMER The information in this content is for educational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have seen in this content. The views expressed here are my own and do not represent the views of my employer or any affiliated institution. Never start, stop, or change the dose of any prescription medication without consulting your physician.
57 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity Sean Hashmi, MD-yhteisöön!